Top Stories Thursday, June 30, 2016 It was a great day for Tesaro yesterday after the biotech posted stellar Phase III results for its PARP inhibitor in ovarian cancer. But following on its good vibes have been other PARP R&D players that all saw their shares jump. The results could make a major difference to the acquisition hopes of Sanofi and Medivation while pulling Clovis out of its shares rut. Wednesday, June 29, 2016 Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes in cancer and immune-mediated diseases. It’s bringing a lead candidate into Phase II around the middle of this year, and now the company has raised $50 million in an IPO to get to that proof-of-concept data. Thursday, June 30, 2016 Shire is having a mixed 24 hours after yesterday posting positive ADHD data for its long-delayed SHP465--which saw its shares rise by 6%--but this morning saw the failure of a Phase II treatment for extremely premature infants. Thursday, June 30, 2016 Bristol-Myers Squibb and PsiOxus Therapeutics have partnered to put a pair of candidates into Phase I testing to treat several tumor types in late-stage cancer patients. The testing will combine the biopharma’s FDA-approved immuno-oncology agent Opdivo (nivolumab) with PsiOxus’ enadenotucirev, an oncolytic adenovirus. Thursday, June 30, 2016 Israeli startup Vidac Pharma has raised $9 million in a Series A raise with the financial boost being led by a new investor, the $100 million Israel Biotech Fund--which has chosen Vidac for its first investment. Thursday, June 30, 2016 Cytune Pharma has secured €6 million to advance its lead candidate into the clinic. The drug, a modified version of interleukin-15, is seen by Cytune as a way to stimulate natural killer and cytotoxic cells, without simultaneously activating regulatory T cells that dampen the immune response. More from EuroBiotech Report Thursday, June 30, 2016 A team of JAMA authors urged the FDA in 2014 to add “black box” warnings to dopamine agonists, linking the Parkinson's meds to pathological gambling, compulsive shopping and sexual obsessions. Now, consumer watchdog Public Citizen is upping the ante, petitioning the agency on behalf of its 400,000 members and citing more than 80 studies supporting its claims. More from FiercePharma
| | | Novartis has published new data for its PKC412 (midostaurin) in the NEJM which shows it achieved a 60% response rate in advanced systemic mastocytosis. Statement New research shows that the world's first malaria vaccine, made by London’s GlaxoSmithKline, provides some protection after 3 doses, but becomes almost ineffective after 7 years. Story | |
|
Resources Sponsored by: SDC Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Covance Al Blunt, MD, Executive Medical Director, Oncology at Covance discusses how the lessons learned from the past decade of developing targeted therapies are relevant to the future development of cancer immunotherapy. Download today! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance.
Characterization of Animal Models for Alzheimer’s disease: Webinar Presented by Charles River July 19, 2016 FierceBiotech Drug Development Forum September 19-21, 2016 | Boston, MA BIOSPAIN 2016 September 28-30, 2016 | Bilbao, Basque Country, Spain BioImmersion: In Depth Biotech for the Non-Scientist October 5-7, 2016 | Chicago, IL 12th Public Relations & Communications Summit July 26-27, 2016 | NYC Immunotherapy: Mapping the future July 28, 2016 | Foster City, CA Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA |
